Navigation Links
After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Date:7/11/2013

EXTON, Pa., July 11, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, for late-phase products for chronic kidney disease (CKD) patients—including AbbVie's altrasentan, Concert Pharmaceuticals' CTP-499, Mitsubishi Tanabe's MP-146/AST-120, Fibrogen's FG3019, Pfizer's PF00487791 and PF04634817 and Eli Lilly's LY2382770—the percentage of likely candidates is typically, but not always highest, in Stage 3b and Stage 4. TreatmentTrends: Chronic Kidney Disease Stages 1-5 ND (US) also finds that, among physicians who treat CKD, familiarity with new products in development is low, but interest is generally high after reviewing brief product profiles.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The report also finds that among 250 surveyed nephrologists, endocrinologists and primary care physicians (PCPs), PCPs are significantly more likely than other physician groups to make the initial diagnosis of CKD, and PCPs account for the majority (51 percent) of the CKD non-dialysis patient referrals that nephrologists receive. Physicians report that CKD patients are most often diagnosed in Stage 3; nephrologists report CKD patients are diagnosed significantly later in the disease process compared with what PCPs and endocrinologists report.

 "Eighty-six percent of physicians believe that the ideal timing for a new CKD agent designed to slow disease progression would be either during treatment of patients with early symptoms or for asymptomatic patients," said BioTrends Research Group Director Rob Dubman. "Given this, these patients are likely to be with the PCP or endocrinologist at that point during the disease progression making these physician types important. Manufacturers in this market should therefore consider, at least to some extent, the impact of the PCP and endocrinologist in regard to patient referral and treatment."

Patient compliance is also a key issue in this patient population. The report finds that patients tend to be most compliant with antihypertensive agents and erythropoiesis stimulating agents (ESAs) and least compliant with phosphate binders and lifestyle changes.

TreatmentTrends: Chronic Kidney Disease Stages 1-5 ND (US) is a report series designed to track physician perception of the CKD non-dialysis patient population, including referral patterns, patient load, percentage of patients on current treatments, screening protocols, diagnosis patterns, frequency of comorbidities, unmet needs and reaction (familiarity, interest and percentage of patients as likely candidates) to new products in development. A total of 250 physicians are included in the third wave sample frame, including 100 nephrologists, 50 endocrinologists and 100 primary care physicians. The third wave of this report published in June 2013. 

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597 
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
3. Parent Project Muscular Dystrophy Endorses Senate Version of Prescription Drug User Fee Act After Patient Voice Strengthened
4. One Year After TomoTherapy Acquisition, Accuray on Track to Meet or Exceed Integration Success Metrics And Expecting Near-term Return to Profitability
5. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
6. Makers Of Over-the-Counter Inhaler Leading Fight To Have Product Back On Market After Removal Due To Environmental Treaty
7. Masimo to Report Second Quarter 2012 Financial Results after Market Close on August 1
8. Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012
9. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
10. Lance Armstrong Update: Arrogant Even After Conceding Doping Charges, Asserts Former White House & WADA Spokesman Robert Weiner; Victory for Clean Sport but "Dark Message" Is Science Must Catch Up to Masking Agents Allowing Cheating
11. Protection Against Whooping Cough Waned During the Five Years After Fifth Dose of DTaP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):